1. Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. (1st October 2022) Authors: Czarnogorski, Maggie; Benn, Paul; McCoig, Cindy; Nwafor, Toyin; Griffith, Sandy; Sutton, Ken; Harrington, Conn; Saggu, Parminder; Yague, Itziar; Williams, Will; Español, Carlos M.; Goodchild, Jessica; Fricker, Jane; Patel, Parul; D'Amico, Ronald Journal: Journal of acquired immune deficiency syndromes Issue: Volume 91:Number 2(2022) Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗